AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Acerca de

Tilray Brands (NASDAQ: TLRY) es una empresa global de cannabis y bienes de consumo envasados que opera en segmentos de cannabis, bebidas alcohólicas, bienestar y distribución, con una presencia significativa en Canadá, Europa y los Estados Unidos. La empresa ha seguido una estrategia de adquisición agresiva, construyendo una de las operaciones de cannabis más grandes del mundo mientras se diversifica hacia cerveza artesanal y destilados a través de la compra de marcas como SweetWater Brewing y Montauk Brewing. Como inversión, Tilray ofrece exposición apalancada a la posible legalización federal del cannabis en EE.UU. y la expansión global de mercados de marihuana legal, aunque los obstáculos persistentes de la industria y la dilución siguen siendo riesgos clave.

Acciones de Cannabis

Tilray Brands es una acción de cannabis importante y una de las mayores empresas de marihuana del mundo por ingresos, con participación de mercado líder en las ventas de cannabis canadiense y una huella internacional creciente en Europa y EE.UU., lo que la convierte en una tenencia clave para inversores que buscan exposición amplia a la industria global del cannabis legal.

Penny Stocks

Tilray Brands cotiza a valoraciones de acciones de centavo después de declives significativos en el precio de las acciones desde sus máximos, representando una oportunidad especulativa para inversores dispuestos a apostar por un repunte de la industria del cannabis y una posible legalización federal estadounidense en un punto de entrada profundamente descontado.

Key Financials TLRY

Precio $7.51
Cambio (1D) +0.27%
Cambio (30D) -16.83%
Cambio (60D) -27.09%
Cambio (90D) -52.47%
Cambio (180D) +66.89%
Cambio (1Y) -20.95%
Cambio (5Y) -98.23%
P/E Ratio 17.88
EPS (TTM) $0.42
Rango de 52 semanas $3.50 — $23.20
MA de 50 días $9.00
Volumen 2.93M

Data updated Feb 15 · Source: Twelve Data

3.7
2 reviews
Risk Profile
3.6
Management Quality
3.4
Valuation
3.3
Fundamentals
3.1
Performance
3
Claude Opus 4.6
AI Review
3.3/5

Tilray Brands is the world's largest cannabis company by revenue, with diversified operations spanning cannabis, craft beer, spirits, and wellness products across multiple continents. The diversification strategy under CEO Irwin Simon has positioned Tilray for potential U.S. federal legalization, though execution has been uneven.

The bull case centers on Tilray's market leadership, international footprint, and a surprisingly reasonable P/E of 17.88 with positive EPS of $0.42"rare profitability in cannabis. The 180-day gain of 66.89% from its $3.50 low shows significant momentum potential when sentiment shifts.

However, the bear case is substantial. The stock has lost 98.23% over five years, reflecting massive shareholder dilution and persistent cash burn historically. The 90-day decline of 52.47% signals renewed selling pressure, and the stock trades well below its 50-day moving average of $9.00. U.S. legalization timelines remain uncertain, and competition intensifies.

Tilray offers high-risk speculative exposure to cannabis with better fundamentals than most peers, but the long-term destruction of shareholder value demands caution. Position sizing is critical here.

Risk Profile
3.6
Management Quality
3.4
Valuation
3.3
Fundamentals
3.1
Performance
3
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.1/5

Tilray Brands (TLRY) presents a unique profile within the cannabis sector, particularly given the data indicating profitability"a rarity among its peers. With a P/E ratio of 18.64 and positive earnings per share of $0.42, the company appears fundamentally healthier than many competitors that struggle with cash burn. Its diversification strategy, blending core cannabis operations with a growing portfolio of craft beverage brands, offers a hedge against regulatory delays.

However, the investment carries significant risk. The stock is currently trading well below its 50-day moving average of $9.02 and has retreated sharply from a 52-week high of $23.20, signaling bearish technical momentum. While the valuation is attractive for a growth-oriented company, the volatility remains high. For investors seeking exposure to the cannabis industry, Tilray offers a compelling, albeit speculative, mix of tangible earnings and global scale, provided one can tolerate the sector's inherent instability.

Feb 11, 2026
Tilray Brands Screenshot

Added: Feb 10, 2026

tilray.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Cómo hacer backtest de una estrategia de trading: métodos, errores y qué significan realmente los resultados

Cómo hacer backtest de una estrategia de trading: métodos, errores y qué significan realmente los resultados

Cada trader tiene una estrategia que se ve genial en su cabeza. El backtesting es cómo descubres si realmente funciona. Aquí hay cómo probar estrategias correctamente, qué métricas importan y por qué la mayoría de los resultados de backtest son demasiado buenos para ser verdad.